Archimedic的动态

Angel Investing in MedTech: 7 Reasons Startups Fail Due Diligence It’s been just over a year since I joined Robin Hood Ventures as an angel investor. And if there’s one thing I’ve learned from diving deep into due diligence, it’s this: the same red flags kill deals over and over again. ?? Here's a brief article on the topic. TLDR; If you’re a MedTech founder raising funds, avoid these common pitfalls: ?? 1. Is the Unmet Need Real? It’s not about what you believe—it’s about cold, hard data. Clinician testimonials aren’t enough. Are providers actively seeking alternatives, or is the status quo good enough? Investors will ask independent experts. Be ready. ?? 2. Is the Market Actually There? TAM-SAM-SOM slides mean nothing if your bottom-up math doesn’t check out. How many real customers exist? What’s a justifiable price point? How often will they use it? If you don’t do the math, investors will—and they won’t like surprises. ?? 3. Will Anyone Pay for It? Better isn’t enough—it has to be worth paying for. Show early willingness-to-pay signals: LOIs, purchasing department feedback, or economic impact data. No clear reimbursement strategy? That’s a problem. ?? 4. Can You Land the Next Round? Most MedTech startups need a $10M+ round to reach an exitable milestone. If VCs aren’t already circling, angels won’t bite. Have you socialized your deal with bigger investors? DD teams will check. ?? 5. Are There Real Exit Opportunities? Who’s actually buying companies like yours? What stage are they acquiring at? If your only M&A comp is from a decade ago, that’s a red flag. Be clear on how and when you’ll exit. ?? 6. Are Your Deal Terms Realistic? Overpriced startups don’t even make it past screening. Work backwards: What return do angels & VCs need? What valuation makes sense based on real exit comps? If your numbers are wishful thinking, expect a quick pass. ?? 7. Are You As Far Along As You Claim? Every startup claims they’re “almost there.” Investors will dissect your tech, regulatory, and clinical milestones. If you’re not ready, own it. Transparency builds trust—overpromising destroys it. ?? Final Takeaway You don’t need all the answers—but strong startups: ? Have deeply researched these issues ? Present data-backed responses ? Show proactive risk mitigation Get ahead of these questions, and you’ll make your MedTech startup far more fundable. What’s been your biggest lesson from MedTech fundraising? Drop it in the comments! ??